Table 1. Summary Data Regarding Patients With AECP.
Screening anti-L-332 ELISAs* | ||||||
---|---|---|---|---|---|---|
Patient | IP | IB | IgG1 | lgG2 | lgG3 | IgG4 |
1 | L-332 | α3 | 0.093 | 0.298 | 0.080 | 0.755 |
2** | L-332 | α3 | 0.195 | 0.208 | 0.097 | 0.510 |
3 | L-332 | α3 | 0.128 | 0.202 | 0.172 | 1.123 |
4** | L-332 | α3 | 0.078 | 0.109 | 0.073 | 0.307 |
5 | L-332 | α3 | 0.074 | 0.134 | 0.064 | 0.525 |
6 | L-332 | α3 | 0.088 | 0.268 | 0.078 | 0.688 |
7** | L-332 | α3 | 0.171 | 0.143 | 0.123 | 0.555 |
8 | L-332 | α3 | 0.076 | 0.217 | 0.063 | 0.083 |
9 | L-332 | α3, γ2 | 0.087 | 0.345 | 0.069 | 0.345 |
10 | L-332 | α3 | 0.170 | 0.334 | 0.087 | 0.640 |
11** | L-332 | α3 | 0.102 | 0.206 | 0.065 | 0.768 |
12 | L-332 | β3, γ2 | 0.099 | 0.174 | 0.078 | 0.597 |
13 | L-332 | α3 | 0.107 | 0.102 | 0.072 | 0.563 |
14 | L-332 | α3, γ2 | 0.089 | 0.156 | 0.074 | 0.381 |
15** | L-332 | α3, β3 | 0.207 | 0.177 | 0.079 | 0.584 |
16 | L-332 | neg | 0.235 | 0.151 | 0.077 | 0.186 |
17 | L-332 | β3 | 0.166 | 0.207 | 0.076 | 0.351 |
18 | L-332 | β3 | 0.115 | 0.299 | 0.081 | 0.631 |
19 | L-332 | α3 | 0.110 | 0.347 | 0.065 | 0.583 |
20 | L-332 | α3 | 0.125 | 0.110 | 0.071 | 0.746 |
21 | L-332 | α3 | 0.101 | 0.159 | 0.076 | 0.334 |
22 | L-332 | α3 | 0.095 | 0.202 | 0.077 | 0.476 |
23 | L-332 | α3 | 0.094 | 0.159 | 0.066 | 0.924 |
24 | L-332 | β3 | 0.089 | 0.183 | 0.065 | 0.415 |
25 | L-332 | α3 | 0.094 | 0.144 | 0.080 | 0.461 |
26 | L-332 | α3 | 0.094 | 0.172 | 0.080 | 0.387 |
27 | L-332 | α3 | 0.147 | 0.251 | 0.108 | 0.606 |
28 | L-332 | neg | 0.161 | 0.254 | 0.089 | 0.387 |
29 | L-332 | α3 | 0.158 | 0.222 | 0.137 | 0.758 |
30 | L-332 | α3 | 0.119 | 0.118 | 0.102 | 0.745 |
31 | L-332 | α3 | 0.099 | 0.190 | 0.094 | 0.786 |
32 | L-332 | α3 | 0.079 | 0.252 | 0.070 | 0.075 |
Reactivity of patient IgG subclasses versus L-332 as scored by OD490 in screening ELISAs. IP, results of immunoprecipitation studies of biosynthetically radiolabeled HK extracts; IB, results of immunoblot studies examining extracts of cultured HKs.
Denotes an AECP patient with cancer.